Conference Summaries: Day Three<BR> Wednesday, July 12, 2000

The Body Covers: The XIII International AIDS Conference

Conference Summaries: Day Three
Wednesday, July 12, 2000

Search through Durban conference original abstracts at the U.S. National Library of Medicine

Post Sexual-Exposure Prophylaxis with HAART After Sexual Assaults
Coverage by Judith Feinberg, M.D.
- Post Sexual-Exposure Prophylaxis with HAART after Sexual Assaults (Poster, WePeC4313)
Sustained Virologic Suppression in Subjects Switched from Protease Inhibitors to Nevirapine
Coverage by Pablo Tebas, M.D.
- Sustained Virologic Suppression in Subjects Switched from Protease Inhibitors (PIS) to nevirapine (NVP) (Poster, WePeB4198)
The Combination of Ritonavir and Amprenavir in Salvage Regimens Overcomes Clinically Multiple-Drug-Resistant HIV (Poster, WePeB4204)
Coverage by Pablo Tebas, M.D.
Hormones and Body Composition
Coverage by Pablo Tebas, M.D.
- Effects of Testosterone and Progressive Resistance Training in Eugonadal Men with AIDS Wasting (Poster, WePpB1383)
New Antiretrovirals -- I
Coverage by Pablo Tebas, M.D.
- DPC 681 and DPC 684: Selective Inhibitors of the Viral Protease Active against Resistant Variants of HIV (WeOrA532)
- Comparative and Combinatorial Analysis of the HIV-1 Entry Inhibitors PRO 542, T-20 and PRO 140 (WeOrA533)
- Potent Antiviral Activity of Second-Generation NNRTIs DPC 961 and DPC 083 against Group M and Group O Strains of HIV-1 (WeOrA536)
Switching Antiretroviral Regimens
Coverage by Pablo Tebas, M.D.
- A Randomized, Controlled, Open-Label Study Comparing the Adherence and Convenience of Continuing Indinavir Q8H vs. Switching to Norvir/Indinavir 400mg/400mg BID (The NICE study) (WeOrB482)
- Effect of Change from TID to BID Nelfinavir (NFV) on Viral Load, CD4 Count and Adherence (WeOrB483)
- A Randomized Study Comparing Continued Indinavir (IDV) (800mg TID) vs. Switching to Indinavir/Ritonavir (RTV) (800/100mg BID) in HIV Patients Having Achieved Viral Load Suppression with Indinavir Plus Two Nucleoside Analogues. The BID Efficacy and Safety Trial (BEST) (WeOrB484)
- Efficacy of Protease Inhibitor Switching to Nevirapine in Patients on HAART with Undetectable Viral Load (WeOrB485)
Co-infection of HIV and Hepatitis Viruses
Coverage by Alvan Fisher, M.D.
- Immunological Responses to Hepatitis C and Non-Hepatitis Antigens in Hepatitis C virus (HCV) Infected and Human Immunodeficiency Virus (HIV)-HCV Coinfected Patients (WeOrA526)
- Seroprevalence Correlates of HIV and HCV Infection among Injection Drug Users (IDUs) Attending an Outreach Syringe Exchange Program (SEPs) in Five Brazilian Cities (WeOrA530)
Emergence of Drug Resistance in the Treatment-Naive Population
Coverage by Alvan Fisher, M.D.
- Transmission of Drug-Resistant HIV-1 in San Francisco (Poster, WePpB1304)
- Epidemiologic Surveillance of HIV Resistance from 1994 to 1999; Increasing Frequency of Naive Patient Mutants (Poster, WePpB1306)
Lipodystrophy and Quality of Life
Coverage by Alvan Fisher, M.D.
- The Impact of Patient Perceptions of Body Shape Changes and Metabolic Abnormalities on Antiretroviral Therapy (Poster, WePpB1380)
Switching Protease Inhibitor to Nevirapine Leads to Reversal of Hyperlipidemia and Lipodystrophy (Poster, WePeB4197)
Coverage by Alvan Fisher, M.D.
The Cost of Managing Abnormal Fat Distribution and Metabolic Abnormalities in France (Poster, WePeB4251)
Coverage by Alvan Fisher, M.D.
Incidence and Associations of Fatigue in HIV-Infected Persons (Poster, WePeC4462)
Coverage by Alvan Fisher, M.D.
Clinical Trials of Antiretroviral Therapy
Coverage by Judith Feinberg, M.D.
- The Effects of Hydroxyurea or Placebo Combined with Efavirenz, Didanosine, and Stavudine in Treatment of Naive and Experienced Patients: Preliminary 24-Week Results from the Third Study (WeOrB603)
- An Open-Label Study to Compare the Efficacy and Safety of the Triple Nucleoside Analog Combination -- Combivir (COM)/Abacavir (ABC) versus a Protease Inhibitor (PI)-Containing Regimen in Antiretroviral Therapy (ART)-Naive Adults (CNAF3007/Ecureuil) (WeOrB605)
- Preliminary Efficacy, Adherence and Satisfaction with COM/ABC Versus COM/IDV, an Open-Label Randomized Comparative Study (CNAB3014) (WeOrB606)
- NZT4002: 64-Week Analysis of Combivir (COM)-Based Triple and Quadruple Therapy in Antiretroviral-Naive, HIV-1-Infected Subjects (WeOrB608)
Responses to Salvage Combination Therapy with Efavirenz in Patients with HIV Who Have Failed Antiretroviral Therapy with a Protease Inhibitor (Poster, WePeB4155)
Coverage by Judith Feinberg, M.D.
Prospective, Multicenter Study of ddI Plus Hydroxyurea Plus Efavirenz Plus Protease Inhibitor Salvage Therapy (Poster, WePeB4164)
Coverage by Judith Feinberg, M.D.
Virologic Response to Indinavir, Efavirenz and Adefovir Among Patients Failing Nelfinavir (Poster, WePeB4169)
Coverage by Judith Feinberg, M.D.
Management of HIV Disease in Real Life
Coverage by Calvin Cohen, M.D.
- Full Plasma Viral Load Suppression is Needed to Achieve an Optimal CD4 Response among Patients Receiving Triple-Drug Antiretroviral Therapy (WeOrB609)
- The Natural History and Clinical Significance of Intermittent Virological "Blips" in Patients Who Attain an Initially Undetectable Viral Load (VL) on HAART (WeB610)
Abacavir, Lamivudine, and Efavirenz
Coverage by Calvin Cohen, M.D.
- Use of Efavirenz in a Low-Income Population (Poster, WePeB4138)
- Evaluation of Novel Combination of Abacavir (ABC), Lamivudine (3TC) and Efavirenz (EFV) (Poster, WePeB4139)
Nelfinavir vs. Indinavir
Coverage by Calvin Cohen, M.D.
- Long-term Comparative Outcomes of Indinavir (IDV) vs. Nelfinavir (NFV)-Based HAART in Naive Patients in Routine Clinical Practice (Poster, WePeB4142)
Response to Salvage with Efavirenz: Implications for Sequencing Antiretroviral Therapy (Poster, WePeB4195)
Coverage by Calvin Cohen, M.D.

Return to The Body's coverage of
The XIII International AIDS Conference.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.